Chickenpox is a common childhood skin disease caused by a viral infection. The virus involved is called the varicella-zoster virus. Today, chickenpox is less common in the United States due to universal vaccination with the varicella virus vaccine, though it still occurs in populations that are not routinely vaccinated. Varicella-zoster virus is often categorized with the other common so-called "viral exanthems" (viral rashes) such as measles (rubeola), German measles (rubella), fifth disease (parvovirus B19), mumps virus, and roseola (human herpesvirus 6), but these viruses are unrelated except for their tendency to cause rashes.
In unimmunized populations, most people contract chickenpox by age 15, the majority between ages 5 and 9, but all ages can contract it. Chickenpox is usually more severe in adults and very young infants than children. Winter and spring are the most common times of the year for chicke...
|
|
ZOVIRAX Ointment (acyclovir ointment) 5% is intended for cutaneous use only and should not be used in the eye.
General: The recommended dosage, frequency of applications, and length of treatment should not be exceeded (see DOSAGE AND ADMINISTRATION). There are no data to support the use of ZOVIRAX Ointment (acyclovir ointment) 5% to prevent transmission of infection to other persons or prevent recurrent infections when applied in the absence of signs and symptoms. ZOVIRAX Ointment (acyclovir ointment) 5% should not be used for the prevention of recurrent HSV infections. Although clinically significant viral resistance associated with the use of ZOVIRAX Ointment (acyclovir ointment) 5% has not been observed, this possibility exists.
Carcinogenesis, Mutagenesis, Impairment of Fertility: Systemic exposure following topical administration of acyclovir is minimal. Dermal carcinogenicity studies were not conducted. Results from the studies of carcinogenesis, mutagenesis, and fertility are not included in the full prescribing information for ZOVIRAX Ointment 5% due to the minimal exposures of acyclovir that result from dermal application. Information on these studies is available in the full prescribing information for ZOVIRAX Capsules, Tablets, and Suspension and ZOVIRAX for Injection.
Pregnancy: Teratogenic Effects: Pregnancy Category B. Acyclovir was not teratogenic in the mouse, rabbit, or rat at exposures greatly in excess of human exposure. There are no adequate and well-controlled studies of systemic acyclovir in pregnant women. A prospective epidemiologic registry of acyclovir use during pregnancy was established in 1984 and completed in April 1999. There were 749 pregnancies followed in women exposed to systemic acyclovir during the first trimester of pregnancy resulting in 756 outcomes. The occurrence rate of birth defects approximates that found in the general population. However, the small size of the registry is insufficient to evaluate the risk for less common defects or to permit reliable or definitive conclusions regarding the safety of acyclovir in pregnant women and their developing fetuses. Systemic acyclovir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Nursing Mothers: It is not known whether topically applied acyclovir is excreted in breast milk. Systemic exposure following topical administration is minimal. After oral administration of ZOVIRAX, acyclovir concentrations have been documented in breast milk in 2 women and ranged from 0.6 to 4.1 times the corresponding plasma levels. These concentrations would potentially expose the nursing infant to a dose of acyclovir up to 0.3 mg/kg per day. Nursing mothers who have active herpetic lesions near or on the breast should avoid nursing.
Geriatric Use: Clinical studies of ZOVIRAX Ointment (acyclovir ointment) did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. Systemic absorption of acyclovir after topical administration is minimal (see CLINICAL PHARMACOLOGY).
Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
Last reviewed on RxList: 8/13/2008
This monograph has been modified to include the generic and brand name in many instances.
Here is a collection of user reviews for the medication Zovirax Ointment sorted by most helpful.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips to boost your love life.
Copyright © 2012 by WebMD, LLC.
RxList does not provide medical advice, diagnosis or treatment. See additional information.
Updated & New